3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
35
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
15
Lung Neoplasms
13
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Neoplasms
10
Colorectal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Head and Neck Neoplasms
4
Carcinoma, Pancreatic Ductal
4
Stomach Neoplasms
3
Neoplasms by Site
3
Gastrointestinal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Adenocarcinoma
3
Vaccinia
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Interventions
Pemetrexed
5
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cisplatin
4
fludarabine
3
Cyclophosphamide
3
Radiotherapy, Intensity-Modulated
2
Cerebral Decortication
2
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
avelumab
1
atezolizumab
1
Platinum
1
LY2940680
1
Influenza Vaccines
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
130-nm albumin-bound paclitaxel
×
90 days
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled